



Market Access for pharmaceutical products, medical devices and digital health applications

Dr. Thomas Ecker


EuHTA Impact on Innovations: Expectations and Challenges of EuHTA for Germany

Copenhagen, Nov. 13th, 2023

Educational Symposium 116





Since 2011 there is a clearly established Market Access workstream for Germany





EU HTA will just add another workload with similar activities




Two propositions – and a conclusion

1

EU HTA follows German HTA mindset, so don't expect surprises.

2

G-BA will always exceed requirements of EU HTA, so EU HTA will not impact decision making in Germany.



So it will not be relevant for stakeholders in Germany. Or will it?



Market Access for pharmaceutical products, medical devices and digital health applications

For more on EU HTA:
- Follow us on LinkedIn
- EU HTA 101